House Subcommittee Hears About Impact of Rising Insulin Prices
A House of Representatives subcommittee heard from stakeholders about the impact of the rising cost of insulin.
Sitting behind 5 vials of insulin, Colorado resident Gail deVore told a House of Representatives subcommittee Tuesday about how the price of insulin has skyrocketed since she was diagnosed as a child with type 1 diabetes in 1972.
Back then, she said, the monthly cost for 4 of those vials was $5. Now, the cash price for those 4 vials is $1400, and even with insurance, the impact is severe, she said.
“It is seriously doubtful that either of us will ever have the opportunity to retire,” deVore said of her and her husband during the hearing, held by the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce.
The hearing is just 1
Rationing and skipping doses is common by patients with diabetes, even though it can lead to fatal or near-fatal complications, witnesses said.
William T. Cefalu, MD, the chief scientific, medical and mission officer for the American Diabetes Association (ADA), referred often to the recommendations of an
“It is unclear precisely how the dollars flow and how much each intermediary profits,” he said. Those profits stem from rising list prices, which are set by drug manufacturers; rebates negotiated by pharmacy benefit managers (PBMs) rise as well, but they are not passed on to the patient.
Kasia J. Lipska, MD, from the Yale-New Haven Hospital Center for Outcomes Research and Evaluation at the Yale University School of Medicine, discussed how 25% of patients with diabetes resort to rationing. In a survey of 199 patients at the Yale Diabetes Center, rationing affected patients across all different prescription coverage plans as well as across most demographic factors, although those with incomes below $100,000 were more likely to ration insulin, she said.
Holding up a vial of Eli Lilly's insulin lispro (Humalog), Lipska noted that it cost $21 in 1996, but now costs over $270. “Eli Lilly has made a big deal about its authorized generic,” she said, referring
“I think we have a moral obligation to address this problem,” she said.
Also Tuesday, the FDA announced it will hold a public hearing May 13 about its plan to transition follow-on insulins to a regulatory pathway for biosimilars.
In 2020, insulins will be regulated as biologics; currently, insulins and a number of other therapies, like hormones, are regulated as drugs and follow-on products. Once insulins are regulated as biologics under section 7002(e) of the Biologics Price Competition and Innovation Act, it will be possible for developers to seek interchangeable designations for their subsequent-entry versions, which will allow for pharmacy-level substitution and
Aaron J. Kowalski, PhD, the chief mission officer of the JDRF, said his organization believes that competition drives innovation and affordability. “We aren’t saying that insulin companies shouldn’t be profitable,” he said. "They're selling insulin abroad at much lower price. The question is how can we make that happen in the United States of America and make sure insulins are affordable?"
“Having generics or biosimilars come to the market is another way of having affordability,” he added.
The hearing will continue next week when it hears from PBM representatives.
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Related Articles
- Nicotinamide Reduces New Skin Cancer Risk in Large Veteran Study
September 23rd 2025
- Childhood Cancer Awareness Month Spotlights Barriers That Persist in Care
September 23rd 2025
- More Effective CKD Strategy Could Have Health, Societal Benefits
September 22nd 2025